USANA Health Sciences (NYSE:USNA – Get Free Report) issued an update on its FY 2025 earnings guidance on Tuesday morning. The company provided EPS guidance of 2.350-3.000 for the period, compared to the consensus EPS estimate of 2.870. The company issued revenue guidance of $920.0 million-$1.0 billion, compared to the consensus revenue estimate of $934.5 million.
USANA Health Sciences Price Performance
NYSE:USNA traded down $0.79 during trading hours on Tuesday, reaching $31.90. The company’s stock had a trading volume of 439,914 shares, compared to its average volume of 145,128. The company has a market cap of $607.96 million, a price-to-earnings ratio of 11.27, a price-to-earnings-growth ratio of 0.93 and a beta of 0.87. USANA Health Sciences has a one year low of $30.13 and a one year high of $50.32. The business’s 50-day moving average is $33.73 and its 200-day moving average is $36.68.
USANA Health Sciences (NYSE:USNA – Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported $0.64 earnings per share for the quarter, topping analysts’ consensus estimates of $0.49 by $0.15. USANA Health Sciences had a return on equity of 10.64% and a net margin of 6.30%. On average, sell-side analysts predict that USANA Health Sciences will post 2.45 EPS for the current fiscal year.
Analyst Upgrades and Downgrades
Get Our Latest Stock Report on USANA Health Sciences
About USANA Health Sciences
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional, personal care, and skincare products in the Asia Pacific, the Americas, and Europe. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers consisting of targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and food that include meal replacement shakes, snack bars, and other related products.
Further Reading
- Five stocks we like better than USANA Health Sciences
- 2 Rising CRM Platform Stocks That Can Surge Higher in 2025
- Nebius Slides Post-Earnings: A Long-Term Buy Opportunity?
- Best Aerospace Stocks Investing
- NVIDIA Stock: A Market Barometer in Tech’s Turbulent Times
- Why Are These Companies Considered Blue Chips?
- Palantir Stock Nears Bear Market Territory – Why and What’s Next?
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.